ATE306938T1 - Verwendung von cpg als adjuvans für hivimpstoff - Google Patents

Verwendung von cpg als adjuvans für hivimpstoff

Info

Publication number
ATE306938T1
ATE306938T1 AT00943919T AT00943919T ATE306938T1 AT E306938 T1 ATE306938 T1 AT E306938T1 AT 00943919 T AT00943919 T AT 00943919T AT 00943919 T AT00943919 T AT 00943919T AT E306938 T1 ATE306938 T1 AT E306938T1
Authority
AT
Austria
Prior art keywords
hiv
cpg
adjuvant
hiv vaccine
vaccine
Prior art date
Application number
AT00943919T
Other languages
English (en)
Inventor
Nathalie Garcon
Gerald Voss
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9915205.0A external-priority patent/GB9915205D0/en
Priority claimed from GB0002200A external-priority patent/GB0002200D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE306938T1 publication Critical patent/ATE306938T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Paper (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT00943919T 1999-06-29 2000-06-28 Verwendung von cpg als adjuvans für hivimpstoff ATE306938T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9915205.0A GB9915205D0 (en) 1999-06-29 1999-06-29 Vaccine
GB0002200A GB0002200D0 (en) 2000-01-31 2000-01-31 Novel use
PCT/EP2000/005998 WO2001000232A2 (en) 1999-06-29 2000-06-28 Use of cpg as an adjuvant for hiv vaccine

Publications (1)

Publication Number Publication Date
ATE306938T1 true ATE306938T1 (de) 2005-11-15

Family

ID=26243523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00943919T ATE306938T1 (de) 1999-06-29 2000-06-28 Verwendung von cpg als adjuvans für hivimpstoff

Country Status (8)

Country Link
US (1) US20080199494A1 (de)
EP (1) EP1198249B1 (de)
AT (1) ATE306938T1 (de)
AU (1) AU5821000A (de)
CA (1) CA2376992A1 (de)
DE (1) DE60023300T2 (de)
ES (1) ES2250151T3 (de)
WO (1) WO2001000232A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
EP1322655B1 (de) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
EP1279404A1 (de) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1450856B1 (de) 2001-09-14 2009-11-11 Cytos Biotechnology AG VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CA2503693A1 (en) 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP1572122A4 (de) 2002-11-01 2008-04-09 Us Gov Health & Human Serv Verfahren zur vorbeugung gegen infektionen von bioterrorismus-agentien mit immunstimulierenden cpg-oligonukleotiden
WO2005090968A1 (en) 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
EP1778282B1 (de) 2004-08-17 2016-03-30 Institut Gustave Roussy Mutiertes hiv nef zur modulation der immunität
WO2007068747A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
JP5437797B2 (ja) 2006-06-12 2014-03-12 サイトス バイオテクノロジー アーゲー Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法
KR20090101313A (ko) * 2007-01-15 2009-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AU2010230073B2 (en) 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
EP3052127A1 (de) 2013-10-04 2016-08-10 PIN Pharma, Inc. Immunstimulierende hiv-tat-derivierende polypeptide zur verwendung bei der krebsbehandlung
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) * 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
IL296071A (en) 2020-03-01 2022-11-01 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
US12605442B2 (en) 2020-03-06 2026-04-21 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5614612A (en) * 1990-03-09 1997-03-25 Haigwood; Nancy L. Purified gp120 compositions retaining natural conformation
KR100194079B1 (ko) * 1990-09-28 1999-06-15 장 스테판느 Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CN1285753A (zh) * 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
AU4992900A (en) * 1999-05-06 2000-11-21 Immune Response Corporation, The Hiv immunogenic compositions and methods

Also Published As

Publication number Publication date
DE60023300D1 (de) 2006-03-02
EP1198249B1 (de) 2005-10-19
ES2250151T3 (es) 2006-04-16
AU5821000A (en) 2001-01-31
US20080199494A1 (en) 2008-08-21
WO2001000232A2 (en) 2001-01-04
EP1198249A2 (de) 2002-04-24
DE60023300T2 (de) 2006-07-06
WO2001000232A3 (en) 2001-05-25
CA2376992A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
BR0113822A (pt) Vacina
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
EP2302059A8 (de) Modifikationen der Env-, Gag- und Pol-Protein des Hiv-Virus erhöhen die Immunogenwirkung genetischer Impfstoffe
CY1111636T1 (el) Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv
BR9814487A (pt) "vacina"
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
FR2792206B1 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
WO2001000231A3 (en) Use of cpg as an adjuvant for malaria vaccine
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
ATE132374T1 (de) Verhütung und behandlung einer retrovirenkrankheit
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
FR2868318B1 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
BR0207931A (pt) Anticorpos naturais ativos contra vìrus hiv
NO980275D0 (no) Dobbelt virusinaktivert humant blodplasma, blodplasmaderivater fremstilt derav og fremgangsmåte for deres fremstilling
FR2792204B1 (fr) Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
DK1150981T3 (da) Terapeutisk necleosidforbindelse
CY1108543T1 (el) Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties